Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization.

By D. Keith, G. Nichols, C. Gullion, Jonathan B. Brown, David H. Smith. Archives of Internal Medicine, 2004

1,708 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/1438c30503c5f5717f03e0964ac33179ae3a876a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Prevalence of chronic kidney disease in population-based studies: Systematic review (2008, background): “However, patients with early stages of CKD are clearly at risk for cardiovascular diseases [46].”
Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. (2007, background): “Patients with CKD are far more likely to die, principally from CVD, than to develop kidney failure.(11) There is now convincing evidence that CKD can be detected using simple laboratory tests, and that certain http://www.”
Survival advantages of obesity in dialysis patients. (2005, background): “CKD patients have a high mortality rate, because many of them have severe and complex comorbid conditions, such as diabetes mellitus, hypertension, and atherosclerotic vascular disease (85).”
Comparison of risk prediction using the CKD-EPI equation and the MDRD Study equation for estimated glomerular filtration rate (2012, neutral): “Information about ethical review of individual studies is available in the publications of the constituent cohorts.(21,24,27-69)”
Prevalence of chronic kidney disease in the United States. (2007, background): “buminuria is the strongest risk factor for CKD progression, it is also associated with an increased risk of cardiovascular morbidity and mortality.(13) Chronic kidney disease stages 3 and 4 are marked by complications of reduced GFR.”
Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality (2014, neutral): “4) KPNW 1997 866 326 4 (3-7) 69 20 5 (2) 438 116 5 (2) 26 27 13 (7-20) n/a n/a n/a 13 13 4 (2) KSHS 2002-09 222 32,733 2 (2-2) 3 155 3 (2) 135 26,539 3 (3-4) 1 76 2 (1) Maccabi 2007-12 30,187 611,799 2 (2-3) 816 207 4 (1) 7,865 17,953 4 (1) 25,358 535,068 5 (3-7) 601 156 2 (1) 4,619 10,552 2 (1) MAS”
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. (2011, background): “disease, one of the four major NCDs prioritized in the Global NCD Action Plan (see below).(24,25,27) The most obvious societal effect of CKD is the enormous financial cost and loss of productivity associated with advanced kidney disease.”